BioCentury | Aug 31, 2009
Company News

Cosmix molecular biologicals GmbH, Opsonic, Tripep deal

...cancer and infectious diseases. Cosmix and Tripep will each receive a 20% stake in Opsonic. Cosmix molecular biologicals GmbH...
BioCentury | Apr 12, 2004
Company News

Cosmix molecular biologicals GmbH, Phylos deal

...Cosmix received a non-exclusive license to Phylos' PROfusion mRNA-peptide display technology. Cosmix molecular biologicals GmbH , Braunschweig, Germany Phylos...
BioCentury | Apr 14, 2003
Company News

Borean management update

Borean Pharma A/S , Aarhus, Denmark Business: Protemics Hired: Riku Rautsola as president and CEO, formerly CEO of Cosmix Molecular Biologics Ltd. ; he succeeds Hans Christian Thoegersen, who becomes CSO WIR Staff...
BioCentury | Dec 17, 2001
Emerging Company Profile

m-phasys: Crystal clear GPCRs

...targets and receive back lead compounds. As part of that effort, in January m-phasys and Cosmix Molecular Biologicals GmbH...
BioCentury | Sep 4, 2001
Company News

Cosmix molecular biologicals GmbH management update

Cosmix molecular biologicals GmbH, Braunschweig, Germany Business: Combinatorial biology Hired: Riku Rautsola as CEO, formerly head of worldwide marketing of prescription medicines at Boehringer Ingelheim GmbH ; he replaces John Collins, who will become CTO...
BioCentury | Aug 31, 2001
Company News

Cosmix names new CEO

Cosmix molecular biologicals (Braunschweig, Germany) hired Riku Rautsola as CEO. He replaces John Collins, who will become CTO. Riku was formerly head of worldwide marketing of prescription medicines at Boehringer Ingelheim . BC Staff...
BioCentury | Jan 22, 2001
Company News

Cosmix Molecular Biologicals GmbH, m-phasys deal

...will jointly develop their respective products, and develop GPCR-targeted proteins and peptides for third parties. Cosmix Molecular Biologicals GmbH...
BioCentury | Aug 28, 2000
Finance

Despite pullback, Germany looks robust

...antiviral, which it licensed from ICN, generated $110 million in royalties in 1999. Private rounds Cosmix molecular biologicals...
Items per page:
1 - 8 of 8
BioCentury | Aug 31, 2009
Company News

Cosmix molecular biologicals GmbH, Opsonic, Tripep deal

...cancer and infectious diseases. Cosmix and Tripep will each receive a 20% stake in Opsonic. Cosmix molecular biologicals GmbH...
BioCentury | Apr 12, 2004
Company News

Cosmix molecular biologicals GmbH, Phylos deal

...Cosmix received a non-exclusive license to Phylos' PROfusion mRNA-peptide display technology. Cosmix molecular biologicals GmbH , Braunschweig, Germany Phylos...
BioCentury | Apr 14, 2003
Company News

Borean management update

Borean Pharma A/S , Aarhus, Denmark Business: Protemics Hired: Riku Rautsola as president and CEO, formerly CEO of Cosmix Molecular Biologics Ltd. ; he succeeds Hans Christian Thoegersen, who becomes CSO WIR Staff...
BioCentury | Dec 17, 2001
Emerging Company Profile

m-phasys: Crystal clear GPCRs

...targets and receive back lead compounds. As part of that effort, in January m-phasys and Cosmix Molecular Biologicals GmbH...
BioCentury | Sep 4, 2001
Company News

Cosmix molecular biologicals GmbH management update

Cosmix molecular biologicals GmbH, Braunschweig, Germany Business: Combinatorial biology Hired: Riku Rautsola as CEO, formerly head of worldwide marketing of prescription medicines at Boehringer Ingelheim GmbH ; he replaces John Collins, who will become CTO...
BioCentury | Aug 31, 2001
Company News

Cosmix names new CEO

Cosmix molecular biologicals (Braunschweig, Germany) hired Riku Rautsola as CEO. He replaces John Collins, who will become CTO. Riku was formerly head of worldwide marketing of prescription medicines at Boehringer Ingelheim . BC Staff...
BioCentury | Jan 22, 2001
Company News

Cosmix Molecular Biologicals GmbH, m-phasys deal

...will jointly develop their respective products, and develop GPCR-targeted proteins and peptides for third parties. Cosmix Molecular Biologicals GmbH...
BioCentury | Aug 28, 2000
Finance

Despite pullback, Germany looks robust

...antiviral, which it licensed from ICN, generated $110 million in royalties in 1999. Private rounds Cosmix molecular biologicals...
Items per page:
1 - 8 of 8